Brief Digital CBT for Mood and Anxiety Symptoms in Acute Psychiatric Inpatients

Sponsor
Centre for Addiction and Mental Health (Other)
Overall Status
Completed
CT.gov ID
NCT04841603
Collaborator
(none)
24
1
2
29
25.2

Study Details

Study Description

Brief Summary

A randomized control trial examining the feasibility, acceptability, and preliminary efficacy of providing access to the MindShift CBT mobile app via tablet for acute psychiatric inpatients.

Condition or Disease Intervention/Treatment Phase
  • Device: Mindshift CBT
  • Device: Treatment as Usual
N/A

Detailed Description

Psychiatric inpatients expect more psychosocial intervention during their inpatient stay than they receive. During the COVID-19 pandemic, existing interventions have been further reduced. Mood and anxiety symptoms are common for all inpatients across diagnostic categories. Studies have shown that cognitive behavioural therapy (CBT) can be effective for treating these symptoms among inpatients. The purpose of this study is to determine whether the Mindshift CBT app (an app based on principles of cognitive behavioural therapy) is an acceptable, feasible, and useable intervention for inpatients.

The Mindshift CBT app is a tool designed and maintained by Anxiety Canada. It includes tools for daily mood check-ins, healthy thinking, calming intense emotions, and taking actions to change behaviours associated with anxiety and low mood. It also includes information about the common types of anxiety.

The proposed trial includes 12 patients per arm. All participants in control and intervention groups will have access to assigned tablet devices throughout the study period, though only those in the intervention group will have the MindShift CBT app on their device. All participants will undergo assessments at baseline and at the end of the intervention period (1 week).

Study Design

Study Type:
Interventional
Actual Enrollment :
24 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized control trialRandomized control trial
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Brief Digital CBT for Mood and Anxiety Symptoms in Acute Psychiatric Inpatients: a Randomized Feasibility Trial
Actual Study Start Date :
Apr 12, 2021
Actual Primary Completion Date :
May 11, 2021
Actual Study Completion Date :
May 11, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Treatment as usual

Treatment as usual

Device: Treatment as Usual
Treatment as usual. A tablet identical to the intervention group, but without the Mindshift CBT app is available for patients to use during their inpatient stay.
Other Names:
  • Tablet
  • Experimental: Mindshift CBT

    Treatment as usual + Access to Mindshift CBT app

    Device: Mindshift CBT
    A tablet with the Mindshift CBT app installed. Mindshift CBT is a free, evidence based app developed by Anxiety Canada, designed to help users reduce symptoms of anxiety and distress.
    Other Names:
  • CBT mobile app
  • Outcome Measures

    Primary Outcome Measures

    1. Retention rates [1 week]

      Feasibility - whether the intervention is possible in the acute inpatient setting

    2. Recruitment rates [1 week]

      Feasibility - whether the intervention is possible in the acute inpatient setting

    3. Client Satisfaction Questionnaire 8 (CSQ-8) [1 week]

      Acceptability - whether the intervention is appropriate for the acute inpatient setting. The CSQ-8 scores range from 8 to 32, with higher values indicating higher satisfaction with the intervention.

    4. User Experience Questionnaire (UXQ) [1 week]

      Usability - whether the intervention is serviceable for its intended purpose. The UXQ has 11 items exploring characteristics informing usability of mobile apps, each scored from 0-10, for a total score ranging from 10-110 (with larger scores indicating increased usability).

    5. Qualitative Data Analysis [1 week]

      From focus groups, to inform feasibility, usability, and acceptability

    Secondary Outcome Measures

    1. Patient Health Questionnaire 9 (PHQ-9) [1 week]

      Preliminary efficacy - whether symptoms of depression are improved by the intervention. PHQ-9 is scored from 0 to 27 with higher scores indicating increasing severity of symptoms.

    2. General Anxiety Disorder 7 Scale (GAD-7) [1 week]

      Preliminary efficacy - whether symptoms of anxiety are improved by the intervention. GAD-7 total score for the seven items ranges from 0 to 21. Scores of 5, 10, and 15 represent cut points for mild, moderate, and severe anxiety.

    3. Kessler Psychological Distress Scale (K10) [1 week]

      Preliminary efficacy - whether symptoms of distress are improved by the intervention. Scores range from 10 to 50, with increasing scores indicating increasing distress and severity of symptoms.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Admitted to the acute inpatient unit

    • Fluent in English

    • Dynamic Appraisal for Situational Aggression (DASA) score <=3

    • Capable to consent to participation as assessed by the treating physician

    Exclusion Criteria:
    • Diagnosis of moderate-severe learning disability

    • Diagnosis of moderate-severe neurocognitive disorder

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre for Addiction and Mental Health Toronto Ontario Canada M6J1H4

    Sponsors and Collaborators

    • Centre for Addiction and Mental Health

    Investigators

    • Principal Investigator: Ishrat Husain, MBBS, MD (Res.), MRCPsych, Centre for Addiction and Mental Health

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Gaurav Sharma, Resident Physician, Centre for Addiction and Mental Health
    ClinicalTrials.gov Identifier:
    NCT04841603
    Other Study ID Numbers:
    • 116/2020-01
    First Posted:
    Apr 12, 2021
    Last Update Posted:
    Jul 27, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Gaurav Sharma, Resident Physician, Centre for Addiction and Mental Health
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 27, 2021